ADHERE trial - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Is DLL3 becoming the most strategic biomarker target in neuroendocrine oncology?

realme Buds T310 in Agile White: top true wireless earbuds under ₹2,000

realme Buds T310 review: Are these the best budget ANC earbuds under ₹2,000?

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Representative image of a subcutaneous injection being administered to a patient, reflecting the self-injection option available with VYVGART SC for CIDP treatment

Read More

Pharma Industry News

argenx wins EU approval for subcutaneous VYVGART in CIDP, ending 30-year innovation drought in treatment

argenx gains EU approval for subcutaneous VYVGART in CIDP, reshaping autoimmune neurology care with a novel self-injection biologic.

byPallavi Madhiraju

June 21, 2025

web analytics